 |
|
|
|
Eprinomectin
API |
|
|
|
Haorui supplies high quality Eprinomectin API produced by our
GMP facility that has been successfully inspected by the
FDA.
We offer
competitive prices and support our products with reliable technical and
regulatory services. Eprinomectin API is available from R&D to
commercial quantities. Please contact us for more details. |
| |
|
The following
information is provided for general information purposes
ONLY. |
|
|
|
What is Eprinomectin? |
|
The chemical name of eprinomectin is
4"-deoxy-4"-epiacetylamino-avermectin B1. It is a
semi-synthetic member of the avermectin family of
macrocyclic lactones and consists of a mixture of two
homologous components, B1a (not less than 90%) and B1b (not
more than 10%), which differ by a single methylene group at
C26. The structure is shown in Figure 1. The purity of the
compound used in the studies of toxicity was determined to
be 95.1-99.6% by high-performnace liquid chromatography (HPLC). |
| |
Eprinomectin is active in animals against
internal and external parasites. Its precise mode of action,
in common with other avermectins, is unknown, despite many
years of investigation of a
variety of compounds in this class. The effect of
avermectins, including eprinomectin, is mediated via a
specific, high-affinity receptor present in the target
organisms. The physiological response to avermectin binding
is increased membrane permeability to chloride ions, which
is independent of gamma-aminobutyric acid (GABA)-mediated
chloride channels. Although avermectins interact with the
GABA-gated channels, they do so only at very high
concentrations, i.e. about three orders of magnitude greater
than that necessary to activate the
high-affinity receptor. Therefore, the action of the
avermectins at the GABA-gated chloride ion channels is
probably not involved in their nematocidal and insecticidal
activity at therapeutic doses. Activation of the specific
avermectin high-affinity receptor ultimately results in
paralysis and death of the target organism (Turner &
Schaeffer, 1989). The fact that much higher concentrations
of these compounds are needed in mammals than in nematodes
to affect neurological function may be due to lack of a
specific, high-affinity site associated with
neuronal function or to the relatively poor penetration of
these high-compounds into the central nervous system (Lankas
& Gordon, 1989). |
| |
|
Disclaimer:
|
|
Information on this page is provided for
general information purposes. You should not make a clinical
treatment decision based on information contained in this
page without consulting other references including the
package insert of the drug, textbooks and where relevant,
expert opinion. We cannot be held responsible for any errors
you make in administering drugs mentioned on this page, nor
for use of any erroneous information contained on this
page. |
|
|
|
|
|
|
